<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20103">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02031211</url>
  </required_header>
  <id_info>
    <org_study_id>29290</org_study_id>
    <nct_id>NCT02031211</nct_id>
  </id_info>
  <brief_title>Etanercept for the Treatment of CRPS</brief_title>
  <official_title>Etanercept for the Treatment of CRPS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studying the effects of Etanercept (an anti-TNF alpha) on early CRPS.  Our hypothesis is
      that Etanercept will improve patient symptoms if given in early CRPS.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Visual Analog Scale</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The participant will keep a daily record of their pain via the Visual Analog Score.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>CRPS</condition>
  <condition>Chronic Regional Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Etanercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will receive 0.4 mg/kg of Etanercept subcutaneously twice weekly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <arm_group_label>Etanercept</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female pediatric CRPS patients with unilateral CRPS of the lower extremity, ages
             10-17 years of age.

          2. Patients must meet CRPS Type I diagnostic criteria and have current evidence of
             edema, and a temperature difference between the affected and contralateral limb
             ≥1.0°C.

          3. Duration of symptoms less than 4 months.

        Exclusion Criteria:

          1. Active malignancy or history of malignancy.

          2. Active infection.

          3. History of TB or TB exposure.

          4. Pregnancy.

          5. Concomitant disease causing immunocompromise.

          6. Concomitant autoimmune disease such as rheumatoid arthritis, psoriasis, ankylosing
             spondylitis or Crohn's Disease.

          7. Poorly controlled psychiatric disease including anxiety, depression or ADHD.

          8. Hepatic or renal impairment as indicated by serum transaminases and/or creatinine ≥
             150% normal value for age.

          9. Evidence of or history of demyelinating disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 7, 2014</lastchanged_date>
  <firstreceived_date>January 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Complex Regional Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>TNFR-Fc fusion protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
